GEOVAX LABS INC (GOVX) Stock Price, Quote, News and Overview
NASDAQ:GOVX - Nasdaq - US3736786068 - Common Stock - Currency: USD
GOVX Quote, Performance and Key Statistics
0.8295
-0.07 (-8.08%)
The current stock price of GOVX is 0.8295 USD. In the past month the price decreased by -38.56%. In the past year, price decreased by -44.7%.
GOVX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About GOVX
Company Profile
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
Company Info
GEOVAX LABS INC
1900 Lake Park Drive, Suite 380
Smyrna GEORGIA 30080 US
CEO: David A. Dodd
Employees: 17
Company Website: https://www.geovax.com/
Investor Relations: http://www.geovax.com/investors
Phone: 16783847220
GEOVAX LABS INC / GOVX FAQ
What is the stock price of GEOVAX LABS INC today?
The current stock price of GOVX is 0.8295 USD. The price decreased by -8.08% in the last trading session.
What is the ticker symbol for GEOVAX LABS INC stock?
The exchange symbol of GEOVAX LABS INC is GOVX and it is listed on the Nasdaq exchange.
On which exchange is GOVX stock listed?
GOVX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GEOVAX LABS INC stock?
11 analysts have analysed GOVX and the average price target is 14.89 USD. This implies a price increase of 1695.3% is expected in the next year compared to the current price of 0.8295. Check the GEOVAX LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GEOVAX LABS INC worth?
GEOVAX LABS INC (GOVX) has a market capitalization of 11.48M USD. This makes GOVX a Nano Cap stock.
How many employees does GEOVAX LABS INC have?
GEOVAX LABS INC (GOVX) currently has 17 employees.
What are the support and resistance levels for GEOVAX LABS INC (GOVX) stock?
GEOVAX LABS INC (GOVX) has a resistance level at 0.93. Check the full technical report for a detailed analysis of GOVX support and resistance levels.
Is GEOVAX LABS INC (GOVX) expected to grow?
The Revenue of GEOVAX LABS INC (GOVX) is expected to grow by 40.18% in the next year. Check the estimates tab for more information on the GOVX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GEOVAX LABS INC (GOVX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GOVX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GOVX, evaluating the profitability, health, valuation and growth aspects
- GEOVAX LABS INC (GOVX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GEOVAX LABS INC (GOVX) Sales and EPS estimates to see what analysts future expectations are.
- GEOVAX LABS INC (GOVX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GEOVAX LABS INC (GOVX) Insider and Institutional Ownership to learn about the owners and their transactions.
- GEOVAX LABS INC (GOVX) Stock Chart to make your own analysis
- GEOVAX LABS INC (GOVX) Latest news and press-releases to stay up to date.
Does GEOVAX LABS INC (GOVX) stock pay dividends?
GOVX does not pay a dividend.
When does GEOVAX LABS INC (GOVX) report earnings?
GEOVAX LABS INC (GOVX) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of GEOVAX LABS INC (GOVX)?
GEOVAX LABS INC (GOVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.67).
What is the Short Interest ratio of GEOVAX LABS INC (GOVX) stock?
The outstanding short interest for GEOVAX LABS INC (GOVX) is 7.42% of its float. Check the ownership tab for more information on the GOVX short interest.
GOVX Technical Analysis
GOVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GOVX. GOVX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GOVX Financial Highlights
Over the last trailing twelve months GOVX reported a non-GAAP Earnings per Share(EPS) of -5.67. The EPS increased by 76.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -306.43% | ||
| ROE | -495.04% | ||
| Debt/Equity | 0 |
GOVX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to GOVX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 77.48% and a revenue growth 40.18% for GOVX